The RND3 deficiency-mediated glioma cell aberrant proliferation can be blocked by Notch inhibitor compound E treatment or by the knockdown of NOTCH1. Moreover, we found that the expression levels of RND3 were inversely correlated with Notch activities in human GBM tissues. This evidence concerns the gene RND3 and central nervous system cancer.